Albert Lowe
Stock Analyst at Craig-Hallum
(3.49)
# 1,004
Out of 5,182 analysts
11
Total ratings
40%
Success rate
54.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiates: Buy | $140 | $54.00 | +159.26% | 1 | Apr 27, 2026 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $127.08 | +37.71% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $27.64 | +80.90% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $20 | $5.42 | +269.00% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $4.97 | +20.72% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.93 | +1,404.65% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.50 | +214.29% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $1.70 | +371.98% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.58 | +153.97% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.44 | +318.12% | 1 | May 13, 2024 |
Spruce Biosciences
Apr 27, 2026
Initiates: Buy
Price Target: $140
Current: $54.00
Upside: +159.26%
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $127.08
Upside: +37.71%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $27.64
Upside: +80.90%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $20
Current: $5.42
Upside: +269.00%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $4.97
Upside: +20.72%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.93
Upside: +1,404.65%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.50
Upside: +214.29%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $1.70
Upside: +371.98%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.58
Upside: +153.97%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.44
Upside: +318.12%